Deluxe Family: The increase of capital in Haihe Pharmaceuticals and related transactions are still in progress

Deluxe Family announced on the evening of August 20th that there was an abnormal fluctuation in stock trading. As of the date of this announcement, the company's cash increase in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. and the related transaction is still ongoing. This external investment involves new business areas, and the company has made this investment decision cautiously based on strategic planning and the development prospects of the biopharmaceutical industry. However, future actual situations, such as changes in policies and regulations, changes in the market environment, changes in industry competition, and changes in Haihe Pharmaceutical's own factors, will all impact Haihe Pharmaceutical's operating conditions. If the company lacks sufficient understanding and tracking of the biopharmaceutical industry, it may lead to an inability to exert the necessary influence in post-investment management and post-investment empowerment, thereby affecting investment returns